“Retifanlimab Vs Avelumab in Patients With Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”. 2025. Farmeconomia. Health Economics and Therapeutic Pathways 26 (1). https://doi.org/10.7175/fe.v26i1.1574.